Berkshire Hathaway Inc Class B (BRK.B) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- FinancialsSector
- $513.7052W High
- $459.1052W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track Berkshire Hathaway Inc Class B (BRK.B) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Berkshire Hathaway Inc Class B has traded between a low of $459.1 and a high of $513.7, highlighting its annual price range. Buy and sell Berkshire Hathaway Inc Class B shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Most Recent News
Global muscle stimulator market to reach $1.16B by 2035, driven by rising demand in pain management and rehab.
The global muscle stimulator market is projected to grow from $812 million in 2025 to $1.16 billion by 2035, at a CAGR of 3.6%. Growth is fueled by increasing use of neuromuscular electrical stimulation devices for pain management, sports rehabilitat...
Global livestock monitoring market to hit $10.3B by 2030, driven by AI and digital farming tech.
The global livestock monitoring market is expected to grow from $6.2 billion in 2025 to $10.3 billion by 2030, at a CAGR of 10.6%, fueled by the adoption of AI, IoT sensors, and wearable tech in precision farming. Europe leads with the largest market...
Atlas Healthcare Fund's 2020 Eli Lilly bet soared 246%, showcasing early clinical insight in healthcare investing.
Atlas Healthcare Fund, managed by VST Capital, invested in Eli Lilly at around $350 per share in 2020, well before its GLP-1 drug tirzepatide became a major success. The stock now trades above $1,200, reflecting a gain of over 246%. This early invest...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.